The Outcome of Tisagenlecleucel (Tisa-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) CD-19 CAR-T Cell Therapy in Relapsed/Refractory NHL, Real World Data, Single Institution Experience

被引：0
|
作者：
Alasbali, Reem [1 ]
Nasiri, Abdulrahman [1 ]
Adam, Alfadil [1 ]
Alhayli, Saud [1 ]
Chaudhri, Naeem A. [1 ]
Alshaibani, Alfadel [1 ]
Albabtain, Abdulwahab [1 ]
Samarkandi, Hadeel [2 ]
Saad, Ayman [1 ]
Alamer, Abdullah [1 ]
Elhassan, Tusneem Ahmed M. [2 ]
Alzahrani, Hazza A. [1 ]
Ahmed, Syed Osman [1 ]
Rasheed, Walid [1 ]
Elfakih, Riad [1 ]
Aljurf, Mahmoud [1 ]
Ali, D. Alahmari [1 ]
机构：
[1] KFSHRC, Dept Hematol, Stem Cell Transplantat & Cellular Therapy, Riyadh, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia
来源：
BLOOD | 2023年 / 142卷
关键词：
NHL; FL; CAR-T; CRS; ICANS;
D O I：
10.1182/blood-2023-182580
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 47 条
  • [1] The Outcome of Tisagenlecleucel (Tisa-Cel) CD-19 CAR-T Cell Therapy in NHL Relapsed/Refractory Beyond Second Line of Therapy, Single-Center Data
    Alasbali, Reem
    Nasiri, Abdulrahman
    Alhayli, Saud
    Chaudhri, Naeem
    Alshaibani, Alfadel
    Albabtain, Abdulwahab
    Osman, Syed Ahmed
    Rasheed, Walid
    El-Fakih, Riad
    Aljurf, Mahmoud
    Alahmari, Ali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S444 - S445
  • [2] Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
    Badbaran, Anita
    Berger, Carolina
    Riecken, Kristoffer
    Kruchen, Anne
    Geffken, Maria
    Mueller, Ingo
    Kroeger, Nicolaus
    Ayuk, Francis A.
    Fehse, Boris
    CANCERS, 2020, 12 (07) : 1 - 12
  • [3] INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)
    Oluwole, O.
    Jansen, J. P.
    Lin, V
    Chan, K.
    Navale, L.
    Kim, J. J.
    Locke, F. L.
    VALUE IN HEALTH, 2019, 22 : S522 - S522
  • [4] Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity
    Buecklein, Veit
    Blumenberg, Viktoria
    Ackermann, Josephine
    Schmidt, Christian
    Rejeski, Kai
    Mueller, Niklas
    Reischer, Anna
    von Baumgarten, Louisa
    Schoeberl, Florian
    Humpe, Andreas
    von Bergwelt, Michael
    Subklewe, Marion
    BLOOD, 2020, 136
  • [5] Digital PCR assays facilitate accurate in-vivo quantification of CD19-CAR T cells after treatment with Axicabtagene ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel)
    Fehse, B.
    Berger, C.
    Badbaran, A.
    Sonntag, T.
    Kruchen, A.
    Riecken, K.
    Geffken, M.
    Mueller, I.
    Kroeger, N.
    Ayuk, F. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 191 - 192
  • [6] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
    Ball, G.
    Kuruvilla, J.
    Boodoo, C.
    Jain, M. D.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [7] Differential dynamics of response at single cell resolution between axi-cel and tisa-cel CAR-T therapy in refractory B-cell lymphomas
    Haradhvala, Nicholas J.
    Leick, Mark B.
    Maurer, Katie
    Gohil, Satyen
    Larson, Rebecca C.
    Yao, Estelle
    Frigault, Matthew J.
    Li, Shuqiang
    Livak, Kenneth J.
    Rhrissorrakrai, Kahn
    Utro, Filippo
    Levovitz, Chaya
    Jacobs, Raquel A.
    Slowik, Kara
    Danysh, Brian P.
    Parida, Laxmi
    Wu, Catherine J.
    Getz, Gad
    Maus, Marcela V.
    CANCER RESEARCH, 2022, 82 (12)
  • [8] Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
    Nastoupil, Loretta J.
    Jain, Michael D.
    Spiegel, Jay Y.
    Ghobadi, Armin
    Lin, Yi
    Dahiya, Saurabh
    Lunning, Matthew A.
    Lekakis, Lazaros J.
    Reagan, Patrick M.
    Oluwole, Olalekan O.
    McGuirk, Joseph P.
    Deol, Abhinav
    Sehgal, Alison R.
    Goy, Andre
    Hill, Brian T.
    Andreadis, Charalambos
    Munoz, Javier
    Westin, Jason R.
    Chavez, Julio C.
    Cashen, Amanda F.
    Bennani, Nora N.
    Rapoport, Aaron P.
    Vose, Julie M.
    Miklos, David B.
    Neelapu, Sattva S.
    Locke, Frederick L.
    BLOOD, 2018, 132
  • [9] Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
    Sharp, John
    Strati, Paolo
    Bhatta, Subodh
    Huang, Jennifer J.
    Thomas, Colin
    Reef, Daniel K.
    Gorzewski, Alexander
    Reinert, Catherine
    Teferra, Andinet
    Pelcovits, Ari
    Ollila, Thomas
    Maakaron, Joseph E.
    Kamdar, Manali K.
    Fitzgerald, Lindsey
    Karmali, Reem
    Grover, Natalie
    Barta, Stefan K.
    Voorhees, Timothy
    Shadman, Mazyar
    Ahmed, Sairah
    Epperla, Narendranath
    BLOOD, 2024, 144 : 2377 - 2378
  • [10] Single- center experience with both Axicabtagene-ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL): Number of prior therapy lines is not associated with progression-free survival
    Buecklein, V
    Blumenberg, V
    Ackermann, J.
    Schmidt, C.
    Rejeski, K.
    Ruzicka, M.
    Mueller, N.
    Reischer, A.
    Busch, G.
    von Baumgarten, L.
    Humpe, A.
    von Bergwelt, M.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 61 - 62
12345